GSKNYSEPharmaceutical PreparationsAlso trades as GLAXF

GSK plc

Financials through fiscal 2025, year ended Dec 31, 2025

$49.46−0.05 (-0.10%)

Close on Oct 19, 2026

GSK plc income statement

AnnualQuarterlyTTM

GBP USD

Millions of GBP, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	32,667	31,376	30,328	29,324	24,696	24,354	33,754	30,821	30,186	27,889	23,923
Cost of Revenue	9,017	9,048	8,565	9,554	8,163	7,929	11,863	10,241	10,342	9,290	8,853
Gross Profit	23,650	22,328	21,763	19,770	16,533	16,425	21,891	20,580	19,844	18,599	15,070
Research & Development	7,525	6,401	6,223	5,488	5,019	4,793	4,568	3,893	4,476	3,628	3,560
Selling, General & Admin	9,088	11,015	9,385	8,372	7,070	7,437	11,402	9,915	9,672	9,366	9,232
Selling & Marketing	202	198	199	192	169	176	393	389	405	395	376
Advertising Expenses	738	851	835	735	433	361	1,567	1,376	1,351	1,265	–
Operating Income	7,932	4,021	6,745	6,433	4,357	5,979	6,961	5,483	4,087	2,598	10,322
Interest Expense	701	669	792	879	769	874	912	798	734	736	757
Interest & Investment Income	169	122	115	76	14	32	98	81	65	72	104
Income from Equity Investments	1.00	-3.00	-5.00	-2.00	33	33	74	31	13	5.00	14
Asset Impairment Charges	1,114	437	507	501	540	712	826	350	1,069	289	587
Pretax Income	7,401	3,477	6,064	5,628	3,599	5,170	6,221	4,800	3,525	1,939	10,526
Income Tax Expense	1,112	526	756	707	83	67	953	754	1,356	877	2,154
Income from Continuing Operations	–	2,951	5,308	4,921	3,516	5,103	–	–	–	–	–
Income from Discontinued Operations	–	0	0	10,700	1,580	1,285	–	–	–	–	–
Net Income incl. Noncontrolling Interests	6,289	2,951	5,308	15,621	5,096	6,388	5,268	4,046	2,169	1,062	8,372
Minority Interest in Earnings	573	376	380	665	711	639	623	423	637	150	-50
Net Income	5,716	2,575	4,928	14,956	4,385	5,749	4,645	3,623	1,532	912	8,422
EPS (Basic)(per share)	1.41	0.63	1.22	3.71	1.10	1.44	1.17	0.92	0.39	0.24	2.18
EPS (Diluted)(per share)	1.39	0.62	1.20	3.66	1.08	1.43	1.16	0.91	0.39	0.23	2.15
Shares Outstanding (Basic, Weighted)(shares)	4,051	4,077	4,052	4,026	4,003	3,981	3,958	3,931	3,909	3,888	3,865
Shares Outstanding (Diluted, Weighted)(shares)	4,117	4,142	4,111	4,084	4,052	4,030	4,013	3,977	3,953	3,927	3,910
EBITDA	10,246	6,572	9,039	8,580	6,479	8,029	9,295	7,339	6,009	4,372	11,952

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 72.4%
Operating margin: 24.3%
Net margin: 17.5%
Return on equity, FY2025: 38.0%

Financial strength

Current ratio: 0.82
Debt to equity: 1.08
Debt to assets: 29.0%
Cash to current liabilities: 15.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.